Il mercato delle terapie ormonali sostitutive mostrerà un CAGR del 6,0% entro il 2026; Aumento della prevalenza dei disturbi della tiroide per stimolare la domanda, afferma Fortune Business Insights
The global hormone replacement therapy market size is predicted to reach USD 20.76 billion by 2026, exhibiting a CAGR of 6.0% during the forecast period. The increasing cases of hormone-related disorders in both men and women of different age groups will spur demand for hormone replacement therapy, which in turn, will boost the hormone replacement therapy market growth during the forecast period. In addition, the increasing prevalence of disorders such as growth deficiency, thyroid disorders, and others will create new sales opportunities for the market in the forthcoming years.
Request a Sample Copy of the Research Report:
According to the report published by Fortune Business Insights, titled “Hormone Replacement Therapy Market Size, Share & Industry Analysis, By Therapy Type (Estrogen and Combinations Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, and Testosterone Replacement Therapy), By Indication (Menopause, Hypothyroidism, Male Hypogonadism, and Growth Hormone Deficiency), By Route of Administration (Oral, Transdermal, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Others), and Regional Forecast, 2019-2026” the market size stood at USD 13.00 billion in 2018. The global hormone replacement therapy market report focuses and elaborates the definition, types, applications and major players in detail. Deep analysis about market status, competition pattern, enterprise, advantages and disadvantages of enterprise products, industry development trends, regional industrial layout characteristics and macroeconomic policies, industrial policy has also been studied and provided within the synopsis. From raw materials to downstream buyers of this industry has been analyzed scientifically, the feature of product circulation and sales channel is presented as well. This report is aimed at helping companies, investors and potential shareholders along with venture capitalists establish a bird’s eye view prospect of industrial development and characteristics of the market. The report also benefits its readers by providing the unrivalled data in well-organized manner.
Approval of Lupin’s Hypothyroidism Treatment Drug by USFDA to Bolster Growth
Lupin Limited, a multinational pharmaceutical company based in Mumbai, Maharashtra, India announced that it has received the approval from the United States Food and Drug Administration (USFDA) to market the tablets for its Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc’s Synthroid Tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. The approval of the novel drugs by the USFDA will be a critical factor in boosting the hormone replacement therapy market revenue during the forecast period due to its use as replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Moreover, Lupin’s spokesperson said in statement, “The product is a generic version of AbbVie Inc’s Synthroid tablets in the same strengths. Furthermore, the growing incidence of menopausal disorders in the developing countries among women will impel companies to launch novel therapeutics, which in turn, will aid the market development.
High Rate Of Hormone Deficiency Disorders to Facilitate Growth in North America
The market in North America generated a revenue of USD 6.89 billion in 2018 and is expected to grow rapidly during the forecast period. The growth in the region is attributed to the rising prevalence of menopause disorders and growing incidence of hormone deficiency disorders. The increasing awareness regarding the therapies among patients will also support growth in the region. Europe is expected to account for a high share in the forthcoming years owing to the surge in hormonal disorders in women. The increasing cases of menopausal disorders and geriatric population suffering from the hypothyroidism will fuel demand for hormone replacement therapy in the region.
The Report List the Main Companies in the Hormone Replacement Therapy Market
- Novo Nordisk A/S
- Pfizer Inc.
- AbbVie Inc.
- Merck KGaA
- Endo Pharmaceuticals Solutions Inc.
- Eli Lilly and Company
- Mithra Pharmaceuticals
Have Any Query? Ask Our Experts: